Hypertension in chronic dialysis patients: Pathophysiology, monitoring, and treatment

American Journal of the Medical Sciences

Volumn 325, Issue 4, 2003, Pages 194-201

  Morse, Stephen A ^b   Dang, An ^b   Thakur, Vashu ^b   Zhang, Rubin ^b   Reisin, Efrain ^a  

^a Department of Medicine   (United States)

^b NONE

Author keywords

Antihypertensive therapy; End stage renal disease; Hemodialysis; Hypertensive mechanisms

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALFACALCIDOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILAZAPRIL; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDRALAZINE; LISINOPRIL; LOSARTAN; METHYLDOPA; METOPROLOL; MINOXIDIL; NADOLOL; NIFEDIPINE; PARATHYROID HORMONE; PROPRANOLOL; RAMIPRIL; RECOMBINANT ERYTHROPOIETIN; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ADRENERGIC SYSTEM; ANEMIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ASTHMA; AUTOIMMUNE DISEASE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; CONSTIPATION; COUGHING; DIALYSIS; DIET RESTRICTION; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; EDEMA; EXERCISE; HEADACHE; HEART FAILURE; HEART PALPITATION; HEMOLYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTRICHOSIS; KIDNEY DISEASE; LIVER TOXICITY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SECONDARY HYPERPARATHYROIDISM; SEDATION; SIDE EFFECT; SMOKING CESSATION; SODIUM RETENTION; SYNCOPE; TACHYCARDIA; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0242499972     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200304000-00005     Document Type: Conference Paper

References (71)

1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9.
2. US Renal Data System. USRDS 2001 Annual Data Report. Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2001.
3. Rostand SG, Brunzell JD, Cannon RO III, et al. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991;2:1053-62.
4. Tomita J, Kimura G, Inoue T, et al. Role of systolic BP in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995;25:405-12.
5. Mittal SK, Kowalski E, Trenkle J, et al. Prevalence of hypertension in a hemodialysis population. Clin Nephrol 1999;51:77-82.
6. Rocco MV, Flanagan MJ, Beaver S, et al. Report from the 1995 Core Indicators for Peritoneal Dialysis study group. Am J Kidney Dis 1997;30:165-73.
7. Coomer RW, Schulman G, Breyer JA, et al. Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. Am J Kidney Dis 1997;29:678-84.
8. London G, Guerin A, Pannier B, et al. Increased systolic pressure in chronic uremia: role of arterial wave reflections. Hypertension 1992;20:10-9.
9. Covic A, Goldsmith DJ. Ambulatory blood pressure monitoring in nephrology: focus on BP variability. J Nephrol 1999;12:220-9.
10. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286-91.
11. Mazzuchi N, Carbonell E, Fernancez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000;58:2147-54.
12. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998;54:561-9.
13. Schömig M, Eisenhardt A, Ritz E. Controversy on optimal blood pressure on hemodialysis: Normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 2001;16:469-74.
14. London GM. Controversy on optimal blood pressure on haemodialysis: lower is not always better. Nephrol Dial Transplant 2001;16:475-9.
15. Rose BD. Natriuretic hormones: atrial peptides and ouabain-like hormone. UpToDate 2000;8:2.
16. Vesely DL, Douglass MSA, Dietz JR, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-34.
17. Cannella G, Castellani A, Mioni G, et al. Blood pressure control in end-stage renal disease in man: indirect evidence of a complex pathogenic mechanism besides renin or blood volume. Clin Sci Mol Med 1977;52:19-21.
18. Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997;48:29-33.
19. Campese VM, Chanana A. Hypertension in dialysis patients. In: Henrich WI, editor. Principles and practice of dialysis, 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1999. p. 209-34.
20. Glatter KA, Graves SW, Hollenberg NK, et al. Sustained volume expansion and (Na-K) ATPase inhibition in chronic renal failure. Am J Hypertens 1994;7:1016-24.
21. Vaughn ED Jr, Carey RM, Ayers CR, et al. Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme. J Clin Endocrinol Metab 1979;48:869-71.
22. Campese VM, Romoff MS, Levitan D, et al. Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 1981;20:246-53.
23. Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-28.
24. Odar-Cederlof I, Ericsson F, Theodorsson E, et al. Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 1998;31:803-8.
25. London G, Marchais S, Guerin AP. Blood pressure control in chronic hemodialysis patients. In: Jacobs C, Kjellstrand CM, Koch KM, et al, editors. Replacement of renal function by dialysis. London: Kluwer; 1997. p. 966-89.
26. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
27. Schmidt RJ, Domico J, Samsell LS, et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999;34:228-34.
28. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
29. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
30. Ritz E, Vallance P, Nowicki M. The effect of malnutrition on cardiovascular mortality in dialysis patients: is L-arginine the answer? Nephrol Dial Transplant 1994;9:129-30.
31. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;7:2453-60.
32. Shichiri M, Hirata Y, Ando K, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1992;15:493.
33. Eschbach JW, Kelly MR, Haley NR, et al. Treatment of anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321:158-63.
34. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991;18(Suppl 1):76-83.
35. Hörl MP, Hörl WH. Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis 2002;39:227-44.
36. Massry SG, Iseki K, Campese VM. Serum calcium, parathyroid hormone and blood pressure. Am J Nephrol 1986;6:119-28.
37. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997;12:933-8.
38. Goldsmith DJ, Covic AA, Venning MC, et al. Blood pressure reduction after patients for secondary hyperparathyroidism: Further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 1996;27:819-25.
39. Anonymous. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
40. Agarwal R. Role of home blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 1999;33:682-7.
41. Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes and future directions. Am J Kidney Dis 1998;32:705-19.
42. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease Am J Kidney Dis 1998;32(Suppl):853-906.
43. Shaldon S. Can antihypertensive medications control BP in haemodialysis patients [letter]? Nephrol Dial Transplant 2000;15:736.
44. Mailloux LU. The overlooked role of salt restriction in dialysis patients [editorial]. Semin Dial 2000;13:150.
45. Charra B, Bergström J, Scribner BH. Blood pressure control in dialysis patients. The importance of the lag phenomenon. Am J Kidney Dis 1998;32:720-4.
46. Donohoe P, Farmer C, Dallyn P, et al. Low sodium haemodialysis without fluid removal improves blood pressure control in chronic dialysis patients [abstract]. Kidney Int 1997;52:1110.
47. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999;10:392-403.
48. Argiles A, Mourad G, Mion C. Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis. N Engl J Med 1998;339:1364-70.
49. Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis 1997;29:383-91.
50. Luik AJ, Charra B, Katzarski K, et al. Blood pressure control and hemodynamic changes in patients on long time dialysis treatment. Blood Purif 1998;16:197-209.
51. Chazot C, Charra B, Laurent G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995;10:831-7.
52. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998;32(Suppl):S120-41.
53. Reisin E. Nonpharmacologic approaches to hypertension: weight, sodium, alcohol, exercise, and tobacco considerations. Med Clin N Am 1997;81:1289-303.
54. Zazgornik J, Biesenbach F, Forstenlehner M, et al. Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT). Clin Nephrol 1997;48:337-440.
55. Rahman M, Dixit A, Donley V, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999;33:498-506.
56. Klingbeil AU, Schmieder RE. Not all left ventricular hypertrophy is created equal. Nephrol Dial Transplant 1999;14:2803-5.
57. Dyadyk AI, Bagriy AE, Lebed IA, et al. ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 1997;12:945-51.
58. Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-8.
59. Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirements in chronic hemodialysis patients. Nephrol Dial Transplant 1995;10:2107-9.
60. Verresen L, Waer M, Vanrenterghem Y, et al. Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990;336:1360-2.
61. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure: dosing guidelines for adults, 4th ed. Philadelphia: American College of Physicians; 1999.
62. Agarwal R, Lewis R, Davis JL, et al. Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 2001;38:1245-50.
63. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
64. Toto R, Shultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension 1998;31:684-91.
65. Saracho R, Martin-Malo A, Martinez I, et al. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int 1998;68(Suppl):S125-9.
66. London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation 1990;82:105-13.
67. Preston RA. Renoprotective effects of antihypertensive drugs. Am J Hypertens 1999;12(Suppl):S19-S32.
68. Agarwal R. Supervised atenolol therapy in management of hemodialysis hypertension. Kidney Int 1999;55:1528-35.
69. Barbour MM, McKindley DS. Pharmacology and pharmacotherapy of cardiovascular drugs in patients with chronic renal disease. Semin Nephrol 2001;21:66-78.
70. Packer M, Bristow MR, Cohn JN, al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
71. Calhoun D, Oparil S, Mathur V, et al. Fenoldopam: a novel peripherally acting dopamine-1-agonist for parenteral treatment of hypertension. Drugs Today 1997;33:729-34.